Trials / Completed
CompletedNCT00005652
Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- University of Alabama at Birmingham · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
OBJECTIVES: I. Determine the response rate and response duration to rituximab in patients with immune thrombocytopenic purpura. II. Evaluate the toxicity associated with this treatment regimen in these patients. III. Evaluate the alteration in antiplatelet antibody with this treatment regimen in these patients.
Detailed description
PROTOCOL OUTLINE: Patients receive rituximab IV on days 1, 8, 15, and 22. Patients who achieve a clinical response lasting over 4 months may receive a second course of rituximab. Patients are followed at 5, 6, 8, and 12 weeks, and then at 6 and 9 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rituximab |
Timeline
- Start date
- 2000-12-01
- Primary completion
- 2007-08-01
- First posted
- 2000-05-03
- Last updated
- 2008-09-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00005652. Inclusion in this directory is not an endorsement.